ArticleHepatology (Baltimore, Md.)2018
Na
Article in Hepatology (Baltimore, Md.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D.Alimentary pharmacology & therapeutics · 2026Article
- Crosstalk between CD8+ T cells and systemic bile acid metabolism shapes antiviral immunity and immunopathology.JCI insight · 2026Article
- Hepatic protein kinase Cβ antagonizing p38American journal of physiology. Gastrointestinal and liver physiology · 2025Article
- Enteronephrohepatic circulation of bile acids and therapeutic potential of systemic bile acid transporter inhibitors.Journal of hepatology · 2025Review
- Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.Hepatology (Baltimore, Md.) · 2025Review
- Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms.Archives of toxicology · 2025Article
- Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response inAmerican journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.Pharmacological reviews · 2024Review
- Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1Journal of lipid research · 2024Article
- The gut microbiota-bile acid axis in cholestatic liver disease.Molecular medicine (Cambridge, Mass.) · 2024Review
- Berberine ameliorates the progression of primary sclerosing cholangitis by activating farnesoid X receptor.Cell biochemistry and biophysics · 2024Article
- Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice.JHEP reports : innovation in hepatology · 2024Article
- Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.JHEP reports : innovation in hepatology · 2023Article
- Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.Cell research · 2022Article
- Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.Seminars in immunopathology · 2022Review
- Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.Journal of hepatology · 2022Article
- Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.Alimentary pharmacology & therapeutics · 2022Article
- Gene Therapy for Acquired and Genetic Cholestasis.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accumulation of bile salts (BSs) during cholestasis leads to hepatic and biliary injury, driving inflammatory and fibrotic processes. The Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.